NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, announced that it has achieved a major milestone in its efforts to expand U.S. production capacity for the important medical radioisotope, molybdenum-99 (Mo-99). The company has received two custom-built IBA Rhodotron®TT 300-HE (High Energy) electron beam accelerators at its facility in Beloit, Wisconsin. The accelerators are critical components in a first-of-its-kind commercial-scale process to produce Mo-99, the parent radioisotope of technetium-99m, the most widely used medical imaging radioisotope, informing healthcare decisions for approximately 40,000 U.S. patients daily.
To read more please visit:
Source: NorthStar Medical Radioisotopes, LLC